The trial will be conducted in two parts, designated Part 1a (dose escalation) and Part 1b (dose expansion). Part 1a is the dose escalation phase of the study and it will proceed in cohorts of up to 6 patients each. Dose escalation will continue until a maximum-tolerated dose (MTD) of AZD5153 monotherapy is reached. AZD5153 is an oral drug and will be taken daily. Alternative dosing schedules may also be evaluated.